利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

93 条记录 (耗时 0.045 秒)

    Cell death-inducing agent
    72.
    发明授权
    Cell death-inducing agent 失效
    细胞死亡诱导剂

    公开(公告)号：US08158385B2

    公开(公告)日：2012-04-17

    申请号：US10530696

    申请日：2003-10-10

    申请人： Shuji Ozaki ,  Masahiro Abe ,  Masayuki Tsuchiya ,  Naoki Kimura ,  Shigeto Kawai

    发明人： Shuji Ozaki ,  Masahiro Abe ,  Masayuki Tsuchiya ,  Naoki Kimura ,  Shigeto Kawai

    IPC分类号： C12P21/04 ,  C12P21/08

    CPC分类号： C07K16/2833 ,  A61K2039/505 ,  C07K14/70539 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/626 ,  C07K2317/73

    摘要： To identify antigens of the 2D7 antibody, the present inventors cloned the 2D7 antigen. The results suggested that the 2D7 antigen is an HLA class I molecule. Based on this finding, the present inventors examined whether the 2D7 antibody has cell death-inducing activity. Nuclei fragmentation was observed when the 2D7 antibody was cross-linked with another antibody, indicating that cell-death was induced. Further, diabodies of the 2D7 antibody were found to have very strong cell death-inducing activities, even without the addition of another antibody. These results indicate that minibodies of an HLA-recognizing antibody can be used as cell death-inducing agents.

    摘要翻译： 为了鉴定2D7抗体的抗原，本发明人克隆了2D7抗原。 结果表明，2D7抗原是HLA I类分子。 基于该发现，本发明人检查了2D7抗体是否具有细胞死亡诱导活性。 当2D7抗体与另一种抗体交联时，观察到细胞核碎裂，表明诱导细胞死亡。 此外，发现2D7抗体的双抗体具有非常强的细胞死亡诱导活性，即使没有添加另一种抗体。 这些结果表明HLA识别抗体的小体抗体可以用作细胞死亡诱导剂。

    Reshaped human antibody to human interleukin-6 receptor
    77.
    发明授权
    Reshaped human antibody to human interleukin-6 receptor 失效
    重组人抗人白细胞介素-6受体

    公开(公告)号：US07479543B2

    公开(公告)日：2009-01-20

    申请号：US10837904

    申请日：2004-05-04

    申请人： Masayuki Tsuchiya ,  Koh Sato ,  Mary Margaret Bendig ,  Steven Tarran Jones ,  Jose William Saldanha

    发明人： Masayuki Tsuchiya ,  Koh Sato ,  Mary Margaret Bendig ,  Steven Tarran Jones ,  Jose William Saldanha

    IPC分类号： C07K16/00

    CPC分类号： C07K16/2866 ,  A61K38/00 ,  C07K2317/24 ,  C07K2319/00

    摘要： A reshaped human antibody to the human IL-6R, comprising: (A) an L chain comprising, (1) a human L chain C region, and (2) an L chain V region comprising human L chain framework regions (FRs), and mouse L chain complementary determination regions (CDRs) of a momoclonal antibody to the IL-6 receptor (IL-6R); and (B) an H chain comprising, (1) a human H chain C region, and (2) an H chain V region comprising human H chain FRS, and mouse H chain CDRs of a monoclonal antibody to the IL-6R. Since major portion of the reshaped human antibody is derived from a human antibody and the mouse CDRs which are less immunogenic, the present reshaped human antibody is less immunogenic to human, and therefor is promised for therapeutic uses.

    摘要翻译： 对人IL-6R的重构人抗体包含：（A）包含（1）人L链C区的L链，和（2）包含人L链框架区（FR）的L链V区， 和IL-6受体（IL-6R）的单克隆抗体的小鼠L链互补决定区（CDR）; 和（B）包含（1）人H链C区和（2）包含人H链FRS的H链V区的H链和与IL-6R的单克隆抗体的小鼠H链CDR。 由于重构的人抗体的大部分衍生自人抗体和免疫原性较小的小鼠CDR，所以本发明的重组人抗体对人的免疫原性较低，因此被用于治疗用途。

    Cell Death Inducing Agents
    79.
    发明申请
    Cell Death Inducing Agents 审中-公开
    细胞死亡诱导剂

    公开(公告)号：US20070280951A1

    公开(公告)日：2007-12-06

    申请号：US10582304

    申请日：2004-12-10

    申请人： Naoki Kimura ,  Masayuki Tsuchiya ,  Masahiko Nanami ,  Takashi Tomimatsu ,  Shigeto Kawai

    发明人： Naoki Kimura ,  Masayuki Tsuchiya ,  Masahiko Nanami ,  Takashi Tomimatsu ,  Shigeto Kawai

    IPC分类号： A61K39/395 ,  A61P35/00 ,  A61P37/00 ,  C07H21/00 ,  C07K16/00 ,  C12N1/00 ,  C12N15/63 ,  C12N5/00 ,  C12P21/00

    CPC分类号： C07K16/00 ,  C07K2317/622 ,  C07K2317/73

    摘要： The present inventors constructed a DNA expression vector encoding 2D7sc(Fv)2 in which the heavy chain variable region sequence (VH) and the light chain variable region sequence (VL) of the 2D7 antibody is arranged in the order of VH-VL-VH-VL, and these sequences are linked by a 15-mer linker. The vector was introduced into CHO cells and a 2D7sc(Fv)2-producing expression cell line was established. When 2D7sc(Fv)2 was expressed in this cell line, purified, and cell death-inducing experiments performed, 2D7sc(Fv)2 was found to have a concentration-dependent cell death-inducing activity.

    摘要翻译： 本发明人构建了编码2D7sc（Fv）2的DNA表达载体，其中2D7抗体的重链可变区序列（VH）和轻链可变区序列（VL）以VH-VL-VH -VL，并且这些序列通过15聚体连接子连接。 将载体导入CHO细胞，并建立产生2D7sc（Fv）2的表达细胞系。 当在该细胞系中表达2D7sc（Fv）2时，发现2D7sc（Fv）2的纯化和细胞死亡诱导实验具有浓度依赖性细胞死亡诱导活性。